Analyst Kostas Biliouris of BMO Capital maintained a Buy rating on Centessa Pharmaceuticals, retaining the price target of $35.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kostas Biliouris has given his Buy rating due to a combination of factors that highlight the potential of Centessa Pharmaceuticals in the orexin agonist market. The recent success of TAK’s Oveporexton in meeting all primary and secondary endpoints in Phase III studies for narcolepsy type 1 (NT1) significantly reduces the risk associated with the orexin agonist class. This success is seen as a positive indicator for Centessa’s own orexin agonist, ORX750, which is expected to offer a competitive advantage in the NT2 and idiopathic hypersomnia (IH) markets.
Biliouris also notes the favorable safety profile of TAK-861, which enhances confidence in the safety of orexin agonists, including Centessa’s pipeline. The absence of severe adverse events and the manageable nature of common side effects further support the potential of Centessa’s offerings. Additionally, upcoming data readouts for Centessa’s ORX750 and ORX142 are anticipated to be key catalysts, potentially driving significant stock movement. These factors collectively underpin Biliouris’s optimistic outlook and Buy rating for Centessa Pharmaceuticals.
Based on the recent corporate insider activity of 86 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CNTA in relation to earlier this year.